[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616345":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":20,"responsibleParty":93,"collaborators":95,"id":99,"slug":10,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":100,"sex":106,"minAge":107,"maxAge":10,"enrollmentInfo":108,"targetDuration":10,"studyType":111,"phases":10,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":22,"whyStopped":10,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"Rijnstate Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with painful chemotherapy induced peripheral neuropathy (CIPN)",null,"Subjects diagnosed with painful CIPN and eligible for SCS implantation",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Esmee Van Leeuwen, MSc","CONTACT","088 005 8888","evanleeuwen@rijnstate.nl",{"name":19,"role":15,"phone":10,"phoneExt":10,"email":10},"Nick Koning, MD PhD",[21,41,54,67,80],{"facility":5,"status":22,"city":23,"state":10,"zip":24,"country":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Arnhem","6815 AD","Netherlands",{"type":27,"coordinates":28},"Point",[29,30],5.91111,51.98,{"lat":30,"lon":29},[33,34,36,39],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":10,"role":15,"phone":10,"phoneExt":10,"email":35},"jkallewaard@rijnstate.nl",{"name":37,"role":38,"phone":10,"phoneExt":10,"email":10},"Nick J Koning, MD PhD","PRINCIPAL_INVESTIGATOR",{"name":40,"role":38,"phone":10,"phoneExt":10,"email":10},"Jan Willem Kallewaard, MD PhD",{"facility":42,"status":22,"city":43,"state":10,"zip":10,"country":25,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"Sint Antonius Ziekenhuis","Nieuwegein",{"type":27,"coordinates":45},[46,47],5.08056,52.02917,{"lat":47,"lon":46},[50],{"name":51,"role":15,"phone":52,"phoneExt":10,"email":53},"Harold Nijhuis, MD","+3188 320 3000","h.nijhuis@antoniusziekenhuis.nl",{"facility":55,"status":22,"city":56,"state":10,"zip":10,"country":25,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Bravis Hospital","Roosendaal",{"type":27,"coordinates":58},[59,60],4.46528,51.53083,{"lat":60,"lon":59},[63],{"name":64,"role":15,"phone":65,"phoneExt":10,"email":66},"Lars Elzinga, MD","+3188 706 8000","l.elzinga@bravis.nl",{"facility":68,"status":22,"city":69,"state":10,"zip":10,"country":25,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"ETZ","Tilburg",{"type":27,"coordinates":71},[72,73],5.0913,51.55551,{"lat":73,"lon":72},[76],{"name":77,"role":15,"phone":78,"phoneExt":10,"email":79},"Johan van de Minkelis, MD","+3113 221 0000","jl.vandeminkelis@etz.nl",{"facility":81,"status":22,"city":82,"state":10,"zip":10,"country":25,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"ASZ","Zwijndrecht",{"type":27,"coordinates":84},[85,86],4.63333,51.8175,{"lat":86,"lon":85},[89],{"name":90,"role":15,"phone":91,"phoneExt":10,"email":92},"Hans Aukes, MD","+3178654 22 19","h.aukes@asz.nl",{"type":94,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[96],{"name":97,"class":98},"Saluda Medical Pty Ltd","INDUSTRY","100616345",false,"NCT07304401","Evaluation of Effectiveness of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy for Treatment of Chemotherapy Induced Peripheral Neuropathy","Assessment of Effectiveness of Closed-loop Spinal Cord Stimulation (CL-SCS) Therapy on Pain Reduction and Improvement of Quality of Life in Patients With Chemotherapy Induced Peripheral Neuropathy","CIPRESS","* Subject is deemed a suitable candidate for SCS implantation and has been routinely scheduled to undergo an SCS implantation with the Evoke SCS System.\n* Subject has a minimum of leg or arm pain intensity of 5\u002F10 on the numeric rating scale (NRS) at baseline due to CIPN.\n* Patients with CIPN following chemotherapy and at least 6 months post-treatment\n* CIPN symptoms for a minimum duration of 3 months.\n* Patient deemed to be in remission per discretion of treating oncologist\n* No existing contraindications for SCS\n* Subject is ≥ 18 years old.\n* Subject is not pregnant or nursing.\n* Subject is willing and capable of giving informed consent.\n* No satisfactory treatment effect with anti-neuropathic medication or intolerable side-effects\n* No satisfactory treatment effect with minimal invasive pain treatments (including ketamine or lidocaine infusion therapy)\n\nExclusion Criteria:\n\n* Patient refusal to be included in study\n* Patients unwilling or mentally incapable to complete the study questionnaires\n* Other causes of neuropathy (for example diabetic- or small fiber neuropathy)\n* Previous treatment with SCS for CIPN\n* Presence of another pain syndrome unrelated to CIPN\n* History of lower limb amputation or ulceration\n* Body mass index (BMI) ≥ 40\n* Severe psychiatric or neurological disorders\n* Any other contra indication for locoregional anaesthesia","ALL","18 Years",{"count":109,"type":110},20,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the effectiveness of closed-loop spinal cord stimulation (CL-SCS) therapy for treatment of painful chemotherapy induced peripheral neuropathy.\n\nThe closed-loop SCS (CL-SCS) system stimulates the nerves in the spinal cord, measures their responses and automatically adjust the stimulation level accordingly in real time for each delivered pulse.",[114,115],"Chemotherapy Induced Peripheral Neuropathy (CIPN)","Neuropathic Pain",[117,118,119,120,121,122],"CIPN","Chemotherapy induced peripheral neuropathy","Spinal Cord Stimulation","SCS","Closed-Loop","neuropathic pain","2025-12-24",{"date":125,"type":126},"2025-12-26","ACTUAL",{"date":128,"type":110},"2025-12-01",{"date":130,"type":110},"2028-12-01",{"name":5,"class":6},5]